Τίτλος:
Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. Methods: A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. Results: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. Conclusions: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function. © 2019 Canadian Cardiovascular Society
Συγγραφείς:
Makavos, G.
Ikonomidis, I.
Andreadou, I.
Varoudi, M.
Kapniari, I.
Loukeri, E.
Theodoropoulos, K.
Pavlidis, G.
Triantafyllidi, H.
Thymis, J.
Parissis, J.
Tsoumani, M.
Rafouli-Stergiou, P.
Katsimbri, P.
Papadavid, E.
Περιοδικό:
Canadian Journal of Cardiology
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
carbonyl derivative; cyclosporine; interleukin 17; malonaldehyde; methotrexate; secukinumab; biological marker; IL17A protein, human; immunosuppressive agent; interleukin 17; monoclonal antibody; secukinumab, adult; arterial stiffness; Article; comparative study; controlled study; coronary flow reserve; diastole; female; heart left ventricle function; heart performance; human; major clinical study; male; myocardial disease; oxidative stress; Psoriasis Area and Severity Index; psoriasis vulgaris; psoriatic arthritis; pulse wave; blood; brachial artery; diagnostic imaging; echocardiography; heart left ventricle function; heart ventricle; middle aged; pathophysiology; physiology; procedures; prognosis; psoriasis; randomized controlled trial, Antibodies, Monoclonal, Humanized; Biomarkers; Brachial Artery; Cyclosporine; Echocardiography; Female; Heart Ventricles; Humans; Immunosuppressive Agents; Interleukin-17; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis; Pulse Wave Analysis; Vascular Stiffness; Ventricular Function, Left
DOI:
10.1016/j.cjca.2019.06.021
